Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell...

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Research

Background:

• Immune checkpoint inhibitors (anti-PD-1/anti-PD-L1) offer new treatment options for advanced non-small cell lung cancer (NSCLC).
• Monotherapy with these agents yields approximately 20% response rates in second-line treatment.
• Identifying predictive biomarkers is crucial for treatment decisions and cost-effectiveness.

Purpose of the Study:

• To review the current landscape of predictive biomarkers for anti-PD-1/anti-PD-L1 therapies in NSCLC.
• To evaluate the utility and limitations of PD-L1 expression as a predictive marker.
• To explore alternative and complementary biomarkers.

Main Methods:

• Review of existing literature on PD-L1 expression and other potential biomarkers in NSCLC.
• Analysis of studies investigating the association between biomarker status and response to anti-PD-1/anti-PD-L1 therapy.
• Discussion of methodological considerations for biomarker assessment.

Main Results:

• PD-L1 expression, assessed by immunohistochemistry, is the most studied predictive biomarker for anti-PD-1/anti-PD-L1 therapies.
• Higher PD-L1 positivity generally correlates with increased response rates.
• The predictive accuracy of PD-L1 expression is not definitive, necessitating exploration of other markers like programmed death-ligand 2, IFN-γ, and genetic signatures.

Conclusions:

• Standardized methods for evaluating PD-L1 expression (e.g., tissue handling, positivity thresholds, managing heterogeneity) are essential for its reliable use as a predictive marker.
• The predictive value of PD-L1 may be influenced by combination therapies.
• Further research into diverse biomarkers is warranted to optimize patient selection for immunotherapy in NSCLC.